Bladder cancer malignant tumor cure rate

The cure rate of bladder cancer is related to the patient's stage, pathological type and treatment method. Early detection and timely treatment are the key to improving the cure rate. The 5-year survival rate of early bladder cancer can reach more than 80%, while the cure rate of late stage cancer will be significantly reduced.

The cure rate of bladder cancer mainly depends on the tumor stage. Non-muscle invasive bladder cancer (NMIBC) is an early stage with relatively good treatment effects. The lesions are usually removed by transurethral resection of bladder tumors (TURBT), and intravesical chemotherapy or immunotherapy (such as BCG) is combined after surgery to prevent recurrence. The survival rate of most patients is high. If bladder cancer enters the muscle invasive (MIBC) stage, partial or radical bladder resection (cystectomy) is usually required, combined with postoperative adjuvant chemotherapy (such as cisplatin combination regimen) or immune checkpoint inhibitor treatment, but the risk of tumor metastasis increases and the cure rate is reduced to about 40%-60%. In advanced bladder cancer with distant metastasis, the possibility of cure is low, but chemotherapy, immunotherapy (such as PD-1/PD-L1 inhibitors) and targeted therapy (such as FGFR inhibitors) can improve the patient's quality of life and prolong survival.

The cure rate of bladder cancer mainly depends on the tumor stage. Non-muscle invasive bladder cancer (NMIBC) is an early stage with relatively good treatment effects. The lesions are usually removed by transurethral resection of bladder tumors (TURBT), and intravesical chemotherapy or immunotherapy (such as BCG) is combined after surgery to prevent recurrence. The survival rate of most patients is high. If bladder cancer enters the muscle invasive (MIBC) stage, partial or radical bladder resection (cystectomy) is usually required, combined with postoperative adjuvant chemotherapy (such as cisplatin combination regimen) or immune checkpoint inhibitor treatment, but the risk of tumor metastasis increases and the cure rate is reduced to about 40%-60%. In advanced bladder cancer with distant metastasis, the possibility of cure is low, but chemotherapy, immunotherapy (such as PD-1/PD-L1 inhibitors) and targeted therapy (such as FGFR inhibitors) can improve the patient's quality of life and prolong survival.

Prevention and early intervention are important steps to improve the cure rate of bladder cancer. Smokers are advised to quit smoking as soon as possible, reduce exposure to harmful chemicals in the environment, and regular physical examinations can help with early detection. Unexplained hematuria should be examined by a doctor as soon as possible, including urine cytology, cystoscopy and other diagnostic methods. After diagnosis, it is necessary to follow the doctor's advice to choose an appropriate treatment plan and postoperative follow-up plan to reduce the risk of recurrence and increase survival.